Stoke Therapeutics Innovates RNA Medicine with TANGO Technology for Genetic Disorder Treatments

Stoke Therapeutics Advances RNA Medicine with Innovative Technology

Stoke Therapeutics, Inc., a biotechnology company based in Bedford, Massachusetts, focuses on pioneering RNA medicine to restore protein expression in patients suffering from genetic disorders. The company employs its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) technology to develop antisense oligonucleotides (ASOs), which are designed to selectively restore protein levels in various diseases, particularly those associated with haploinsufficiency. This innovative approach addresses the critical challenge of diseases where patients experience a loss of approximately 50% of necessary protein levels, leading to severe health issues.

Currently, Stoke's lead candidate, zorevunersen (STK-001), is undergoing clinical trials for Dravet syndrome, a debilitating genetic epilepsy characterized by significant neurological challenges. The company is also progressing with STK-002, targeted at treating autosomal dominant optic atrophy (ADOA), the most prevalent inherited disorder affecting the optic nerve. Stoke's focus on haploinsufficiencies, particularly within the central nervous system and ocular diseases, highlights its commitment to addressing urgent medical needs. Furthermore, the company has demonstrated proof of concept for its technology across various organs and systems, indicating the potential for wider applications beyond its current targets.

Stoke Therapeutics not only emphasizes advancing treatment for specific disorders but also aims to position itself as a leader in RNA-targeting strategies. The company plans to share its insights and developments at the upcoming 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025. During this event, management will present the company's latest advancements, underscoring its ongoing commitment to innovative solutions in biotechnology. Stakeholders and interested parties can access the presentation via a live audio webcast, with a replay available for 30 days post-event.

In addition to its lead candidates, Stoke Therapeutics is continually exploring new avenues for its TANGO technology, which holds promise for addressing a range of unmet medical needs. The company operates from its headquarters in Bedford and a research facility in Cambridge, Massachusetts, reflecting its robust infrastructure to support cutting-edge research and development. By leveraging its RNA-targeting strategies, Stoke Therapeutics aims to significantly improve patient outcomes in various debilitating conditions. For further information about the company's initiatives and progress, stakeholders are encouraged to visit Stoke's official website.